Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by equities researchers at Cantor Fitzgerald to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.
Bradmer Pharmaceuticals Price Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- Why is the Ex-Dividend Date Significant to Investors?
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- How to Calculate Stock Profit
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What Does Downgrade Mean in Investing?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
